The case now proceeds to discovery on the breach of contract claim. Monitor for settlement discussions or further dispositive motions. Given the age of the drug (Forteo patents expired 2019) and Lilly's $1.1T market cap, any potential damages are likely small relative to the company's size.
Price Chart
Executive Summary
The Seventh Circuit reversed the district court's dismissal of Teva's breach of contract claim against Eli Lilly, allowing the case to proceed. The ruling is procedural—it does not award damages or issue an injunction—and merely holds that Teva plausibly alleged that Lilly's covenants under a 2018 settlement agreement regarding the osteoporosis drug Forteo remained in effect after patent expiration. For a $1.1 trillion market cap company, the financial exposure is not quantified in the opinion and is likely immaterial.
Court Ruling Details
Key Facts
- Seventh Circuit reversed dismissal of Teva's breach of contract claim against Lilly (No. 25-2125).
- Ruling holds that the 2018 settlement agreement's covenants not to obstruct Teva's generic Forteo entry could plausibly survive patent expiration.
- Case remanded to district court for further proceedings; no damages awarded or quantified in the opinion.
- Lilly's Forteo patents expired August 19, 2019; the alleged breaches occurred in 2020–2023.
Financial Impact
No damages awarded; potential exposure not quantified in the opinion.
Risk Factors
- Adverse ruling on summary judgment or at trial could result in damages, but magnitude uncertain.
- Discovery may reveal additional exposure or lead to settlement costs.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-25219da5fd-LLY |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 5w ago | Press Release | $1,115.70 $1,179.27 | ▲ +5.70% | ▲ +3.83% | $1,257.03 (+12.67%) |
Sep 8, 2026 5w ago | Court Ruling | $1,123.91 $1,157.49 | ▲ +2.99% | ▲ +1.02% | $1,257.03 (+11.84%) |
Aug 18, 2026 8w ago | Insider Cluster | $1,225.73 $1,137.82 | ▼ −7.17% | ▼ −5.86% | $1,257.03 (+2.55%) |
Aug 11, 2026 9w ago | Insider Cluster | $1,215.02 $1,124.21 | ▼ −7.47% | ▼ −6.42% | $1,257.03 (+3.46%) |
Aug 7, 2026 10w ago | Court Ruling | $1,185.71 $1,149.36 | ▼ −3.07% | ▼ −2.67% | $1,257.03 (+6.01%) |
Aug 5, 2026 10w ago | 8-K | $1,169.86 $1,160.08 | ▼ −0.84% | ▼ −0.23% | $1,257.03 (+7.45%) |
Aug 4, 2026 10w ago | Court Ruling | $1,115.68 $1,160.00 | ▲ +3.97% | ▲ +5.21% | $1,257.03 (+12.67%) |
Jul 31, 2026 11w ago | Court Ruling | $1,148.84 $1,174.61 | ▼ −2.24% | ▲ +0.74% | $1,257.03 (−9.42%) |
Jul 30, 2026 11w ago | Court Ruling | $1,154.97 $1,176.10 | ▲ +1.83% | ▼ −2.14% | $1,257.03 (+8.84%) |
Jul 22, 2026 12w ago | Press Release | $1,163.01 $1,280.34 | ▲ +10.09% | ▲ +7.19% | $1,257.03 (+8.08%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access